AXA Framlington Biotech R Class Acc

Performance History30/06/2019
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech R Class Acc
Fund11.2-5.98.5-7.315.6
+/-Cat-2.3-1.9-1.70.61.3
+/-B’mrk-7.10.3-2.6-4.12.6
 
Key Stats
NAV
19/07/2019
 GBX 183.40
Day Change 0.49%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB0031007254
Fund Size (Mil)
30/06/2019
 GBP 430.95
Share Class Size (Mil)
19/07/2019
 GBP 108.35
Max Initial Charge 5.50%
Ongoing Charge
12/10/2018
  1.82%
Investment Objective: AXA Framlington Biotech R Class Acc
The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Fund may also invest in other transferable securities and units in collective investment schemes. The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.
Returns
Trailing Returns (GBP)19/07/2019
YTD17.19
3 Years Annualised7.46
5 Years Annualised11.74
10 Years Annualised16.55
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
05/07/2012
Dani Saurymper
01/04/2015
Inception Date
26/11/2001
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  AXA Framlington Biotech R Class Acc31/05/2019
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock95.070.0095.07
Bond0.000.000.00
Property0.000.000.00
Cash4.890.544.35
Other0.590.000.59
Top 5 Regions%
United States84.05
Eurozone5.96
Europe - ex Euro3.66
Japan3.03
United Kingdom1.71
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Gilead Sciences IncHealthcareHealthcare7.33
Celgene CorpHealthcareHealthcare6.90
Alexion Pharmaceuticals IncHealthcareHealthcare6.80
Biogen IncHealthcareHealthcare6.21
Amgen IncHealthcareHealthcare4.65
AXA Framlington Biotech R Class Acc
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites